EDIT Editas Medicine, Inc.
Price Chart
Executive Summary
Editas Medicine reported Q1 2026 EPS of -$0.26, slightly worse than the -$0.24 consensus (a miss), while revenue of $2.8M fell short of the $5.9M estimate. The company highlighted progress with its lead in vivo candidate EDIT-401, but also disclosed an adverse USPTO ruling reaffirming the Broad Institute's CRISPR/Cas9 patent position, creating legal overhang. Cash burn continues with $123.6M remaining, expected to fund operations into Q3 2027.
Actionable Insight
The revenue miss and adverse patent ruling are near-term headwinds, but EDIT-401's preclinical momentum could drive upside if early human data is positive. Monitor for first-in-human trial initiation and proof-of-concept data by year-end 2026; the Jefferies conference on June 4 may provide further pipeline updates.
Key Facts
- Q1 2026 EPS: -$0.26 vs consensus -$0.24 (miss of 8.3%)
- Q1 2026 revenue: $2.8M vs consensus $5.9M (miss of 52.5%)
- Net loss narrowed to $25.0M from $76.1M YoY, driven by restructuring and discontinuation of reni-cel program
- Cash and equivalents: $123.6M, down from $146.6M at year-end 2025
- USPTO reaffirmed Broad Institute's patent position in CRISPR/Cas9 interference, adverse for Editas
- EDIT-401 preclinical data shows >90% LDL-C reduction; first-in-human trial expected later in 2026 with proof-of-concept data by year-end
- Company expects cash runway into Q3 2027
Financial Impact
Revenue miss of ~$3.1M (52.5% below consensus); EPS miss of $0.02 (8.3% below consensus); cash burn of $23.0M in Q1
Risk Factors
- Adverse USPTO patent ruling creates uncertainty around CRISPR/Cas9 licensing and potential royalty obligations
- Revenue miss of 52.5% vs consensus signals lack of near-term commercial revenue
- Cash burn rate implies limited runway beyond Q3 2027 without additional financing
- EDIT-401 is still preclinical; clinical failure or delay would eliminate pipeline value
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287494 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $2.49 awaiting T+5 | awaiting T+5 | — | $2.50 (+0.60%) |
|
May 26, 2026
17d ago
|
424B5
| $3.57 $2.82 | ▲ +21.01% | ▲ +22.22% | $2.50 (+29.97%) |
|
May 26, 2026
17d ago
|
8-K
| $3.57 $2.82 | ▲ +21.01% | ▲ +22.22% | $2.50 (+29.97%) |
|
May 26, 2026
17d ago
|
Press Release
| $3.08 $3.34 | ▼ −8.44% | ▼ −7.36% | $2.50 (+18.83%) |
|
May 26, 2026
18d ago
|
8-K
| $3.08 $3.34 | ▲ +8.44% | ▲ +7.36% | $2.50 (−18.83%) |
|
May 26, 2026
18d ago
|
424B5
| $3.08 $3.34 | ▼ −8.44% | ▼ −7.36% | $2.50 (+18.83%) |
|
May 26, 2026
18d ago
|
Press Release
| $3.08 $3.34 | ▼ −8.44% | ▼ −7.36% | $2.50 (+18.83%) |
|
May 26, 2026
18d ago
|
Press Release
| $3.08 $2.82 | ▼ −8.44% | ▼ −9.65% | $2.50 (−18.83%) |
|
May 14, 2026
4w ago
|
8-K
| $2.85 $2.67 | ▼ −6.32% | ▼ −5.60% | $2.50 (−12.28%) |
|
May 14, 2026
4w ago
|
Press Release
| $2.85 $2.67 | ▼ −6.32% | ▼ −5.60% | $2.50 (−12.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access